Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the tolerability and safety of RKI983 ophthalmic solution and explore the effect of the compound on intraocular pressure in subjects with ocular hypertension.

• Phase: Phase 1

Details

• Lead Sponsor: Novartis

Criteria

Inclusion Criteria:

• Males and females, ≥18 years of age, with primary open angle glaucoma and ocular hypertension

• Females must be post-menopausal or surgically sterile

Exclusion Criteria:

• Other types of glaucoma

• Eye pressure lowering surgeries

• A history of or current eye conditions or medical problems that would prohibit the use of an investigational drug

Other protocol-defined inclusion/exclusion criteria may apply.